# A Study of Safety, PK, & PD of ISIS 416858 Administered Subcutaneously to Patients With End-Stage Renal Disease on Hemodialysis

> **NCT02553889** · PHASE2 · COMPLETED · sponsor: **Ionis Pharmaceuticals, Inc.** · enrollment: 49 (actual)

## Conditions studied

- End-stage Renal Disease (ESRD)

## Interventions

- **DRUG:** ISIS 416858
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02553889
- **Lead sponsor:** Ionis Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-10
- **Primary completion:** 2016-11
- **Final completion:** 2016-11
- **Target enrollment:** 49 (ACTUAL)
- **Last updated:** 2016-12-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02553889

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02553889, "A Study of Safety, PK, & PD of ISIS 416858 Administered Subcutaneously to Patients With End-Stage Renal Disease on Hemodialysis". Retrieved via MORVS 2026-10-09 from https://api.morvs.ai/clinical/NCT02553889. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*